Objective:

To evaluate the efficacy and safety of upadacitinib in East Asian patients with moderately to severely active Crohn's disease (CD) based on phase 3 clinical trials.

Approach:

• Study Design: Post hoc analysis of phase 3, multicenter, double-blind, placebo-controlled trials assessing upadacitinib for CD.
• Patient Population: Included patients aged 18-75 from Japan, China, Korea, Taiwan, Hong Kong, Singapore, and Malaysia with moderately to severely active CD.
• Treatment Protocol: Patients were randomized to receive upadacitinib 45 mg daily or placebo for 12 weeks, followed by maintenance therapy for 52 weeks.
• Outcome Assessments: Clinical and endoscopic outcomes were assessed at 12 weeks for induction and 52 weeks for maintenance.

Key Findings:

• Upadacitinib demonstrated efficacy in achieving clinical and endoscopic remission in East Asian patients with CD.
• Safety profile of upadacitinib was consistent with previous reports across other indications.

Interpretation:

The findings suggest that upadacitinib may be a viable treatment option for East Asian patients with moderately to severely active CD.

Limitations:

• The analysis is post hoc and may be subject to biases inherent in such evaluations.
• Limited generalizability due to the specific demographic and geographic focus on East Asian populations.

Conclusion:

Upadacitinib shows promise as an effective treatment for Crohn's disease in East Asian patients, addressing a significant unmet need in this population.

Sources:

• Clinical Trials